indapamide has been researched along with Obesity in 11 studies
Indapamide: A benzamide-sulfonamide-indole derived DIURETIC that functions by inhibiting SODIUM CHLORIDE SYMPORTERS.
indapamide : A sulfonamide formed by condensation of the carboxylic group of 4-chloro-3-sulfamoylbenzoic acid with the amino group of 2-methyl-2,3-dihydro-1H-indol-1-amine.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess real-life effectiveness of a perindopril/indapamide (Per/Ind) single-pill combination (SPC) in patients with hypertension (HT) and type 2 diabetes mellitus (T2DM), obesity and/or metabolic syndrome (MetS)." | 9.12 | Beneficial Effects of a Perindopril/Indapamide Single-Pill Combination in Hypertensive Patients with Diabetes and/or Obesity or Metabolic Syndrome: A Post Hoc Pooled Analysis of Four Observational Studies. ( Brzozowska-Villatte, R; De Champvallins, M; Dézsi, CA; Farsang, C; Glezer, M; Karpov, Y, 2021) |
| "To assess real-life effectiveness of a perindopril/indapamide (Per/Ind) single-pill combination (SPC) in patients with hypertension (HT) and type 2 diabetes mellitus (T2DM), obesity and/or metabolic syndrome (MetS)." | 5.12 | Beneficial Effects of a Perindopril/Indapamide Single-Pill Combination in Hypertensive Patients with Diabetes and/or Obesity or Metabolic Syndrome: A Post Hoc Pooled Analysis of Four Observational Studies. ( Brzozowska-Villatte, R; De Champvallins, M; Dézsi, CA; Farsang, C; Glezer, M; Karpov, Y, 2021) |
| "To study the effectiveness of a fixed combination of perindopril and amlodipine, with the subsequent addition of indapamide-retard in male patients with arterial hypertension (AH), obesity and severe sleep apnea (OSAS)." | 3.88 | The effectiveness of combination antihypertensive therapy in patients with arterial hypertension and additional risk factors: obesity and obstructive sleep apnea syndrome. ( Chazova, IE; Elfimova, EM; Litvin, AY, 2018) |
| " We thus investigated the long-term effects of an angiotensin-converting enzyme (ACE) inhibitor (perindopril)/diuretic (indapamide) combination (per/ind) in the Zucker rat, a classical model of chronic renal failure associated with obesity, hyperlipidemia, and insulin resistance." | 3.72 | Long-term protection of obese Zucker rat kidneys from fibrosis and renal failure with an angiotensin-converting enzyme inhibitor/diuretic combination. ( Belair, MF; Chainey, A; Chevalier, J; Mandet, C; Michel, O; Myara, I; Plante, GE; Renaud, IM, 2004) |
| "Weight loss is strongly recommended for overweight and obese adults with type 2 diabetes." | 2.94 | The Risks of Cardiovascular Disease and Mortality Following Weight Change in Adults with Diabetes: Results from ADVANCE. ( Chalmers, J; Hamet, P; Harrap, S; Lee, AK; Marre, M; Mcevoy, JW; Ohkuma, T; Selvin, E; Sharrett, AR; Wang, D; Warren, B; Williams, B; Woodward, M, 2020) |
| "Telmisartan was more effective, whereas indapamide had better pharmacoeconomic benefits." | 2.80 | Prevention of metabolic disorders with telmisartan and indapamide in a Chinese population with high-normal blood pressure. ( Liu, Z; Lu, F; Peng, J; Tang, M; Wang, Z; Zhang, H; Zhang, W; Zhao, Y; Zhong, M, 2015) |
| " All groups had mean diastolic pressure controlled at or below the 90 mmHg criterion during the period of constant methyldopa dosage for those patients who required Step 2 therapy." | 2.65 | Indapamide in the stepped-care treatment of obese hypertensive patients. ( Godfrey, JC; Neiss, ES; Noble, RE; Vukovich, RA; Webb, EL; Zisblatt, M, 1983) |
| "Treatment with amlodipine, candesartan, or indapamide did not significantly affect plasma visfatin levels." | 1.43 | Effects of antihypertensive treatment on plasma apelin, resistin, and visfatin concentrations. ( Piecha, G; Skoczylas, A; Więcek, A, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 3 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, AK | 1 |
| Woodward, M | 2 |
| Wang, D | 1 |
| Ohkuma, T | 1 |
| Warren, B | 1 |
| Sharrett, AR | 1 |
| Williams, B | 2 |
| Marre, M | 2 |
| Hamet, P | 1 |
| Harrap, S | 1 |
| Mcevoy, JW | 1 |
| Chalmers, J | 2 |
| Selvin, E | 1 |
| Farsang, C | 1 |
| Dézsi, CA | 1 |
| Brzozowska-Villatte, R | 1 |
| De Champvallins, M | 1 |
| Glezer, M | 1 |
| Karpov, Y | 1 |
| Rosolová, H | 1 |
| Mohammedi, K | 1 |
| Herrington, W | 1 |
| Li, Q | 1 |
| Mancia, G | 1 |
| Poulter, N | 1 |
| Rodgers, A | 1 |
| Perkovic, V | 1 |
| Coresh, J | 1 |
| Elfimova, EM | 1 |
| Litvin, AY | 1 |
| Chazova, IE | 1 |
| Peng, J | 1 |
| Zhao, Y | 1 |
| Zhang, H | 1 |
| Liu, Z | 1 |
| Wang, Z | 1 |
| Tang, M | 1 |
| Zhong, M | 1 |
| Lu, F | 1 |
| Zhang, W | 1 |
| Skoczylas, A | 1 |
| Piecha, G | 1 |
| Więcek, A | 1 |
| Kaplan, NM | 1 |
| Toblli, JE | 1 |
| DeRosa, G | 1 |
| Rivas, C | 1 |
| Cao, G | 1 |
| Piorno, P | 1 |
| Pagano, P | 1 |
| Forcada, P | 1 |
| Renaud, IM | 1 |
| Chainey, A | 1 |
| Belair, MF | 1 |
| Mandet, C | 1 |
| Michel, O | 1 |
| Myara, I | 1 |
| Chevalier, J | 1 |
| Plante, GE | 1 |
| Noble, RE | 1 |
| Webb, EL | 1 |
| Godfrey, JC | 1 |
| Zisblatt, M | 1 |
| Vukovich, RA | 1 |
| Neiss, ES | 1 |
1 review available for indapamide and Obesity
| Article | Year |
|---|---|
Beneficial Effects of a Perindopril/Indapamide Single-Pill Combination in Hypertensive Patients with Diabetes and/or Obesity or Metabolic Syndrome: A Post Hoc Pooled Analysis of Four Observational Studies.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Drug Combinations; Humans; | 2021 |
4 trials available for indapamide and Obesity
| Article | Year |
|---|---|
The Risks of Cardiovascular Disease and Mortality Following Weight Change in Adults with Diabetes: Results from ADVANCE.
Topics: Adult; Aged; Body-Weight Trajectory; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Combin | 2020 |
Associations between body mass index and the risk of renal events in patients with type 2 diabetes.
Topics: Aged; Albuminuria; Blood Glucose; Body Mass Index; Creatinine; Diabetes Mellitus, Type 2; Drug Combi | 2018 |
Prevention of metabolic disorders with telmisartan and indapamide in a Chinese population with high-normal blood pressure.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; China; Double-Blind Method | 2015 |
Indapamide in the stepped-care treatment of obese hypertensive patients.
Topics: Adult; Aged; Diuretics; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; | 1983 |
6 other studies available for indapamide and Obesity
| Article | Year |
|---|---|
How to treat arterial hypertension in obese patients?
Topics: Antihypertensive Agents; Diabetes Mellitus, Type 2; Diuretics; Humans; Hypertension; Indapamide; Obe | 2020 |
The effectiveness of combination antihypertensive therapy in patients with arterial hypertension and additional risk factors: obesity and obstructive sleep apnea syndrome.
Topics: Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Drug Combinations; H | 2018 |
Effects of antihypertensive treatment on plasma apelin, resistin, and visfatin concentrations.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; | 2016 |
[The challenge to treat hypertensive patients with type 2 diabetes].
Topics: Adult; Albuminuria; Antihypertensive Agents; Body Mass Index; Cardiovascular Diseases; Diabetes Mell | 2002 |
Cardiovascular protective role of a low-dose antihypertensive combination in obese Zucker rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Cardiova | 2003 |
Long-term protection of obese Zucker rat kidneys from fibrosis and renal failure with an angiotensin-converting enzyme inhibitor/diuretic combination.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Diuretics; Drug Combinations; Fibrosis; Indapamid | 2004 |